BCS Healthcare Practice Management & Consulting Services800-433-1439



Q. How are we certain we are maximizing CRNA reimbursement within our facility?

A. This is an excellent 'opener' at a meeting with facility administration for any department head of an anesthesia department when the topic of anesthesia revenue comes up. Professional services in the anesthesia department may well be the only department within the facility that potentially has untapped revenue available for today's educated and 'street smart' healthcare administrator. I say 'street smart' because today's effective healthcare administrator needs to think entirely 'out of the box' to develop methods of efficiency and revenue enhancement and identification that have not been previously tried and tested within today's healthcare marketplace. Professional services revenue is available to anyone that employs or contracts with anesthesia providers whether physician or CRNA. Another 'out of the box' theory is to grasp professional services revenue and own it, manage it, measure it, and control it so that the employer or contractor of the anesthesia group is in control of the economic drivers that are present within the marketplace for anesthesia. Only then will the 'street smart' healthcare executive maintain the ability to state that they are maximizing their CRNA reimbursement.

In order to determine if your facility can answer this question in the affirmative, you will need to essentially dismantle the anesthesia professional fees within your facility and analyze the current methodology that is in place. The duration or total anesthesia time is only one element of this puzzle and if time is the only element utilized within your institution then financial losses are imminent. BCS has designed our Anesthesia Practice Impact Study process to do just this identify current revenue generators, breakdown their methodology, compare and contrast to industry standards, and layout the changes that are needed to make certain you can affirmatively answer the question, "How are we certain we are maximizing CRNA reimbursement."